Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
- 1 June 2004
- journal article
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (5) , 1225-1227
- https://doi.org/10.1016/j.transproceed.2004.05.067
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Reconstitution of the Epstein-Barr virus–specific cytotoxic T-lymphocyte response following T-cell–depleted myeloablative and nonmyeloablative allogeneic stem cell transplantationBlood, 2003
- Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsBlood, 2003
- Respiratory virus infections in transplant recipients after reduced‐intensity conditioning with Campath‐1H: high incidence but low mortalityBritish Journal of Haematology, 2002
- Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recoveryBlood, 2002
- High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitutionBlood, 2002
- Alemtuzumab in Stem Cell TransplantationMedical Oncology, 2002
- T cell-depleted nonmyeloablative stem cell transplantation: what is the optimum balance between the intensity of host conditioning and the degree of T cell depletion of the graft?Bone Marrow Transplantation, 2001
- In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantationCytotherapy, 2001
- EX VIVO DEPLETION OF T CELLS FROM BONE MARROW GRAFTS WITH CAMPATH-1 IN ACUTE LEUKEMIATransplantation, 1999
- Reshaping human antibodies for therapyNature, 1988